Néovacs
French tech company | Builders Republic
About
Clinical-stage biotech developing active immunotherapy candidates using the proprietary Kinoïde technology — engineering cytokine-derived immunogens to stimulate patient antibody response against excess cytokine production, with pipeline targeting lupus (IFN-alpha Kinoïde) and allergies (IL-4/IL-13/IgE Kinoïde).
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Venture Round
- Founded
- 1993
- City
- SURESNES
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 1.9 M€ raised since 2020
Funding rounds
- Venture Round — 2021
Investors
- European High Growth Opportunities